Flagship Pioneering Special Opportunities Fund II, L.P. has an estimated net worth of $373 Million. This is based on reported shares across multiple companies, which include Omega Therapeutics, Inc., Foghorn Therapeutics Inc., Sigilon Therapeutics, Inc., and Generate Biomedicines, Inc..

2026 was Flagship Pioneering Special Opportunities Fund II, L.P.'s most active year for acquiring shares with 12 total transactions. Flagship Pioneering Special Opportunities Fund II, L.P.'s most active month to acquire stocks was the month of July. 2021 was Flagship Pioneering Special Opportunities Fund II, L.P.'s most active year for disposing of shares, totalling 11 transactions. Flagship Pioneering Special Opportunities Fund II, L.P.'s most active month to dispose stocks was the month of July. 2026 saw Flagship Pioneering Special Opportunities Fund II, L.P. paying a total of $89,999,766.73 for 42,157,156 shares, this is the most they've acquired in one year. In 2023 Flagship Pioneering Special Opportunities Fund II, L.P. cashed out on 797,720 shares for a total of $11,901,982.40, their largest year based on trade value.